Primary focal segmental glomerulosclerosis (FSGS) frequently causes end-stage renal disease (ESRD), requiring dialysis therapy or kidney transplantation. Recurrent FSGS leads to a high rate of subsequent failure of transplanted kidneys with the same disease pathophysiology as the initial presentation, indicating progressive renal damage caused by a conserved, circulating factor in blood. This project aims to identify this factor by screening blood samples from patients affected by FSGS via an in vitro functional assay using our kidney organoid system that will identify high value targets for identification by proteomics. The approach uses an established bank of serum from patients with FSGS (recurrent vs. non-recurrent disease types): 1) Plasma samples are fractionated by chromatography to separate proteome components; 2) Plasma fractions are screened on kidney organoids in a high throughput, multi-plex pathway to evaluate response of organoid cell types.
|Effective start/end date||9/30/18 → 3/31/21|
- U.S. Army Medical Research and Materiel Command (W81XWH1810748)